M Alan BrookhartUniversity of North Carolina at Chapel HillAbstract/ManuscriptApproval & CommercializationYesR&D
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies.
Use of negative control outcomes to assess the comparability of patients initiating lipid-lowering therapies
Challenge
NCOs had been proposed as tools to assess unmeasured confounding in comparative drug studies, but their real-world performance had not been rigorously validated in a large lipid-lowering therapy cohort using an active comparator new-user design.
Solution
Target RWE researchers applied NCOs to a real-world comparative analysis of patients initiating lipid-lowering therapies, demonstrating how NCO balance and imbalance can be used to gauge confounding control success before primary outcomes are analyzed.